Sanofi
Sino Biopharmaceutical Enters Exclusive Global Licensing Agreement with Sanofi for First-in-Class JAK/ROCK Inhibitor Rovadicitinib
2026-03-04
Sanofi’s Venglustat Demonstrates Superiority Over ERT in Phase 3 Type 3 Gaucher Disease Trial
2026-02-02
Next-Generation Vaccines Advance Through Abu Dhabi DoH and Sanofi’s MoU Agreement at US BIO 2025
2025-06-26
Sanofi Acquires Bispecific Drug Candidate in $600 Million Deal Focused on Autoimmune Disorders
2025-03-21
Teva and Sanofi’s Best-in-Class IBD Drug a Game-Changer in the Antibody Therapeutics Arena
2024-12-18
LATEST
David vs. Goliath: Taiwan’s PGI Wins $23M Settlement in Sequencing Patent Dispute with U.S. PacBio
2026-03-13
Gut Microbiome Composition Predicts Long-term Cardiometabolic Health Outcomes in Diverse Urban Populations
2026-03-12
NVIDIA Ahead of GTC 2026: Markets Focus on Data Center Strength, PC Expansion, and the Next Technical Breakout
2026-03-12
Global and APAC Biopharma Watch: Capital Raising, Clinical Expansion, and Industry Moves in Focus
2026-03-12
EVENT
2026-04-09
4th Cell & Gene Therapy Innovation & Access Congress: Asia (Media Partnership)
Seoul, South Korea
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California





